Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.96
CADX's Cash to Debt is ranked higher than
60% of the 1248 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. CADX: 1.96 )
CADX' s 10-Year Cash to Debt Range
Min: 1.96   Max: No Debt
Current: 1.96

Equity to Asset 0.38
CADX's Equity to Asset is ranked higher than
57% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CADX: 0.38 )
CADX' s 10-Year Equity to Asset Range
Min: 0.38   Max: 0.73
Current: 0.38

0.38
0.73
F-Score: 5
Z-Score: 7.17
M-Score: -2.31
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -24.47
CADX's Operating margin (%) is ranked higher than
79% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.88 vs. CADX: -24.47 )
CADX' s 10-Year Operating margin (%) Range
Min: -531.52   Max: -24.47
Current: -24.47

-531.52
-24.47
Net-margin (%) -21.58
CADX's Net-margin (%) is ranked higher than
79% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.05 vs. CADX: -21.58 )
CADX' s 10-Year Net-margin (%) Range
Min: -557.15   Max: -21.58
Current: -21.58

-557.15
-21.58
ROE (%) -59.51
CADX's ROE (%) is ranked higher than
65% of the 1143 Companies
in the Global Biotechnology industry.

( Industry Median: -35.75 vs. CADX: -59.51 )
CADX' s 10-Year ROE (%) Range
Min: -208.02   Max: -56.92
Current: -59.51

-208.02
-56.92
ROA (%) -26.54
CADX's ROA (%) is ranked higher than
74% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: -28.24 vs. CADX: -26.54 )
CADX' s 10-Year ROA (%) Range
Min: -95.75   Max: -25.78
Current: -26.54

-95.75
-25.78
ROC (Joel Greenblatt) (%) -1430.56
CADX's ROC (Joel Greenblatt) (%) is ranked higher than
66% of the 1223 Companies
in the Global Biotechnology industry.

( Industry Median: -438.40 vs. CADX: -1430.56 )
CADX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2914.5   Max: -635.39
Current: -1430.56

-2914.5
-635.39
EBITDA Growth (%) -41.10
CADX's EBITDA Growth (%) is ranked higher than
56% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. CADX: -41.10 )
CADX' s 10-Year EBITDA Growth (%) Range
Min: -55.6   Max: 33.4
Current: -41.1

-55.6
33.4
EPS Growth (%) -36.40
CADX's EPS Growth (%) is ranked higher than
59% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. CADX: -36.40 )
CADX' s 10-Year EPS Growth (%) Range
Min: -54.8   Max: 0.7
Current: -36.4

-54.8
0.7
» CADX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

CADX Guru Trades in Q2 2013

Steven Cohen 16,477 sh (New)
» More
Q3 2013

CADX Guru Trades in Q3 2013

Paul Tudor Jones 30,700 sh (New)
Steven Cohen 6,100 sh (-62.98%)
» More
Q4 2013

CADX Guru Trades in Q4 2013

Jim Simons 54,300 sh (New)
Caxton Associates 75,000 sh (New)
Steven Cohen 17,842 sh (+192.49%)
Paul Tudor Jones 16,706 sh (-45.58%)
» More
Q1 2014

CADX Guru Trades in Q1 2014

Paul Tudor Jones Sold Out
Steven Cohen Sold Out
Jim Simons Sold Out
Caxton Associates Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CADX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 34.95
CADX's P/B is ranked higher than
58% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 6.13 vs. CADX: 34.95 )
CADX' s 10-Year P/B Range
Min: 2.34   Max: 35.03
Current: 34.95

2.34
35.03
P/S 10.59
CADX's P/S is ranked higher than
82% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 28.86 vs. CADX: 10.59 )
CADX' s 10-Year P/S Range
Min: 4.46   Max: 965
Current: 10.59

4.46
965
EV-to-EBIT -44.25
CADX's EV-to-EBIT is ranked higher than
55% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CADX: -44.25 )
CADX' s 10-Year EV-to-EBIT Range
Min: -42.9   Max: -1.8
Current: -44.25

-42.9
-1.8
Current Ratio 2.13
CADX's Current Ratio is ranked higher than
60% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. CADX: 2.13 )
CADX' s 10-Year Current Ratio Range
Min: 2.13   Max: 37.5
Current: 2.13

2.13
37.5
Quick Ratio 1.89
CADX's Quick Ratio is ranked higher than
61% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. CADX: 1.89 )
CADX' s 10-Year Quick Ratio Range
Min: 1.89   Max: 37.5
Current: 1.89

1.89
37.5

Valuation & Return

vs
industry
vs
history
Price/Net Cash 699.00
CADX's Price/Net Cash is ranked higher than
71% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 50.00 vs. CADX: 699.00 )
CADX' s 10-Year Price/Net Cash Range
Min: 4.07   Max: 452.5
Current: 699

4.07
452.5
Price/Net Current Asset Value 93.19
CADX's Price/Net Current Asset Value is ranked higher than
70% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 29.38 vs. CADX: 93.19 )
CADX' s 10-Year Price/Net Current Asset Value Range
Min: 3.95   Max: 60.33
Current: 93.19

3.95
60.33
Price/Tangible Book 49.93
CADX's Price/Tangible Book is ranked higher than
62% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9.38 vs. CADX: 49.93 )
CADX' s 10-Year Price/Tangible Book Range
Min: 3.19   Max: 32.32
Current: 49.93

3.19
32.32
Price/Median PS Value 1.14
CADX's Price/Median PS Value is ranked higher than
83% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. CADX: 1.14 )
CADX' s 10-Year Price/Median PS Value Range
Min: 0.74   Max: 1.64
Current: 1.14

0.74
1.64
Earnings Yield (Greenblatt) -2.30
CADX's Earnings Yield (Greenblatt) is ranked higher than
81% of the 1218 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. CADX: -2.30 )
CADX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 0
Current: -2.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:QEW.Germany,
Cadence Pharmaceuticals, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing product candidates mainly for use in the hospital setting. The Company's main activities are conducting research and development activities as well as conducting clinical trials. The company has in-licensed rights to products: Acetavance, an intravenous formulation of acetaminophen, and Omigard, an omiganan pentahydrochloride 1% aqueous gel. It in-licensed the exclusive United States, or U.S., and Canadian rights to Acetavance from Bristol-Myers Squibb Company, or BMS, which markets this product candidate in Europe and other markets for the treatment of acute pain and fever under the brand name Perfalgan. The Company is developing Acetavance, a proprietary intravenous formulation of acetaminophen, for the U.S. market for the treatment of acute pain and fever in adults and children. In its oral form, acetaminophen is the most widely used drug for the treatment of pain and fever in the U.S. The Company's licensor, BMS, currently markets this proprietary intravenous formulation of acetaminophen for the treatment of acute pain and fever in Europe and several other markets outside the U.S, where it is known as paracetamol and is marketed under the brand name Perfalgan.
» More Articles for CADX

Headlines

Articles On GuruFocus.com
Can Malllinckrodt Keep on Crushing Expectations? Mar 19 2014 
Cadence Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 05 2010 
Cadence Pharmaceuticals Inc. (CADX) President, CEO Theodore R Schroeder sells 50,000 Shares Oct 04 2010 
Cadence Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 06 2010 
Cadence Pharmaceuticals Inc. (CADX) President, CEO Theodore R Schroeder sells 50,000 Shares Jul 01 2010 
Cadence Pharmaceuticals Inc. (CADX) President, CEO Theodore R Schroeder sells 50,000 Shares Apr 01 2010 
Cadence Pharmaceuticals Inc. (CADX) President, CEO Theodore R Schroeder sells 30,000 Shares Jan 04 2010 
Cadence Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 05 2009 
Cadence Pharmaceuticals Inc. (CADX) President, CEO Theodore R Schroeder sells 20,000 Shares Oct 19 2009 
Cadence Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 06 2009 

More From Other Websites
Mallinckrodt to buy Questcor Pharma for $5.6 bn Apr 07 2014
Gabelli liquidates stake in Cadence Mar 20 2014
CADENCE PHARMACEUTICALS INC Files SEC form 8-K, Termination of a Material Definitive Agreement,... Mar 19 2014
Mallinckrodt plc Completes $1.4 Billion Acquisition of Cadence Pharmaceuticals, Inc. Mar 19 2014
CADENCE PHARMACEUTICALS INC Financials Mar 06 2014
Recro Pharma IPO Could Be More Painful Than Expected Mar 05 2014
Wider-Than-Expected Q4 Loss at Cadence Pharma Mar 04 2014
Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results Feb 28 2014
CADENCE PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 28 2014
Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results Feb 28 2014
The Zacks Analyst Blog Highlights: Regeneron, Gilead, Medicines Co., AbbVie and Cadence Feb 20 2014
Lifshitz & Miller Law Firm Announces Investigation of Cadence Pharmaceuticals, Inc., Chindex... Feb 19 2014
SHAREHOLDER DEADLINE: Law Office of Brodsky & Smith, LLC Announces Investigation of Cadence... Feb 17 2014
CADENCE PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of... Feb 14 2014
SHAREHOLDER DEADLINE: Law Office of Brodsky & Smith, LLC Announces Investigation of Cadence... Feb 14 2014
INVESTOR ALERT: LEVI & KORSINSKY, LLP Announces Investigation of CADENCE PHARMACEUTICALS INC. and... Feb 13 2014
Cadence: What To Do With The Proceeds And A Post Mortem On A Successful Investment Feb 13 2014
CADENCE INVESTOR ALERT: Faruqi & Faruqi, LLP is Investigating Cadence Pharmaceuticals, Inc. (CADX)... Feb 13 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK